In the evolving landscape of anticoagulation management, anti-Xa assays have emerged as critical tools for monitoring and assessing both heparin therapy and direct oral anticoagulants (DOACs). This webinar will provide a comprehensive overview of anti-Xa testing, including its clinical applications, advantages over traditional coagulation tests, and best practices for laboratory implementation.
Key Topics
- Principles of anti-Xa Assays: How they work and their role in anticoagulation monitoring.
- Heparin Monitoring: Differences between unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) testing.
- DOAC Testing: When and why anti-Xa assays are used for rivaroxaban, apixaban, and edoxaban measurement.
- Laboratory Best Practices: Standardization, assay selection, and quality control considerations.
Speaker
Dr. John MitsiosÌý
Dr. Mitsios is a Medical Sciences Partner in the Medical Affairs team at Siemens Healthineers. His primary research interest throughout his education and training has been in coagulation, with an emphasis on platelet function and biology. Dr. Mitsios was on the faculty at Weill Cornell University, School of Medicine as an Assistant professor of Pathology and Laboratory Medicine and an Assistant Attending Clinical Chemist at New York-Presbyterian Hospital. In addition, Dr. Mitsios served as an Assistant Director of the Special Coagulation Laboratory at BioReference Laboratories, overseeing the day-to-day activities of the lab, and signing out clinical hemostasis cases.
